Respiratory Syncytial Virus (RSV) Clinical Trial
Official title:
Respiratory Syncytial Virus (RSV) and Vaccination in Pregnancy
Respiratory Syncytial Virus (RSV) is the leading cause of chest infections (pneumonia and
bronchiolitis) in young children, and is a major cause of admission to hospital and childhood
death worldwide. One possible way to protect the mother and young infant from RSV infection
is a vaccine given to women during pregnancy (maternal vaccination), which would pass
protection to their unborn child. This may help to prevent RSV in the child's first few
months of life when they are most vulnerable to infection.
There are two main aims to this study:
1. To pre-emptively gauge the knowledge of RSV and potential acceptability of such vaccines
amongst pregnant women and healthcare staff working in midwifery and obstetrics, as well
as their attitudes (facilitators and barriers) to being involved in hypothetical future
research trials.
2. We also wish to gauge the attitudes to routinely recommended vaccines in pregnancy
(pertussis and influenza)
The investigators propose to undertake a questionnaire-based study of randomly selected
pregnant women and healthcare staff (over 16 years of age) at English teaching hospitals and
GP practices. Pregnant women attending for ward reviews or antenatal clinics will approached
and asked to complete an anonymous paper questionnaire lasting around 10 minutes. Healthcare
staff will be approached in person, or via email, and asked to complete a slightly different
questionnaire lasting around 5-10 minutes. No follow up will take place. Using statistical
software, the investigators hope to identify factors that might affect patients'
understanding of RSV and attitudes to being involved in hypothetical future trials and
receiving routine vaccination
Respiratory Syncytial Virus (RSV) is a very common virus that causes infection of the airways
and lungs. It is the leading cause of chest infections (pneumonia and bronchiolitis) in young
children, and is a major cause of admission to hospital and childhood death worldwide. Lots
of research trials are being done into ways of preventing and treating RSV, however there is
still no RSV vaccine approved for routine use. One possible way to protect the mother and
young infant from RSV infection is a vaccine given to women during pregnancy, which would
pass protection to their unborn child. This may help to prevent RSV in the child's first few
months of life when they are most vulnerable to infection. There are two vaccines that are
currently being tested in pregnant women around the world, including the UK.
There are two main aims to this study:
1. To pre-emptively gauge the knowledge of RSV and potential acceptability of such vaccines
amongst pregnant women and healthcare staff working in midwifery and obstetrics, as well
as their attitudes (facilitators and barriers) to being involved in hypothetical future
research trials.
2. We also wish to gauge the attitudes to routinely recommended vaccines in pregnancy
(pertussis and influenza)
The investigators propose to undertake a questionnaire-based study of randomly selected
pregnant women and healthcare staff (over 16 years of age) at four English teaching
hospitals. Pregnant women attending for ward reviews or antenatal clinics will approached and
asked to complete an anonymous paper questionnaire lasting around 10 minutes. Healthcare
staff will be approached in person, or via email, and asked to complete a slightly different
questionnaire lasting around 5-10 minutes. No follow up will take place. Using statistical
software, the investigators hope to identify factors that might affect patients'
understanding of RSV and attitudes to being involved in hypothetical future trials and
receiving routine vaccination
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02593071 -
Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.
|
Phase 2 | |
| Completed |
NCT02266628 -
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
|
Phase 2 | |
| Completed |
NCT02282982 -
Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
|
N/A | |
| Completed |
NCT01704365 -
RSV-F Vaccine Dose Ranging Study in Young Women
|
Phase 2 | |
| Completed |
NCT01709019 -
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
|
Phase 1 | |
| Recruiting |
NCT06185647 -
Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
|
||
| Recruiting |
NCT04925310 -
Infection With Respiratory Syncytial Virus in Infants
|
||
| Completed |
NCT02968173 -
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
|
Phase 3 | |
| Active, not recruiting |
NCT06077149 -
Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
|
Phase 4 | |
| Completed |
NCT02608502 -
A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
|
Phase 3 | |
| Recruiting |
NCT05047549 -
Community-based RSV Surveillance in Infant Mortality: Minimally Invasive Tissue Sampling Study in Karachi, Pakistan
|
||
| Terminated |
NCT04225897 -
A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.
|
Phase 2 | |
| Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
| Not yet recruiting |
NCT06216093 -
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
|
Phase 1 | |
| Completed |
NCT04927793 -
Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT05443607 -
Transplacental Transmission of RSV (TTRSV)
|
||
| Recruiting |
NCT04896853 -
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
|
Phase 1 | |
| Active, not recruiting |
NCT03916185 -
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT05842967 -
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
|
Phase 3 | |
| Recruiting |
NCT04909021 -
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
|
Phase 1 |